# Transcend Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/transcend-therapeutics-2

- Industry: Biotechnology
- Headquarters: New York, US
- Website: www.transcendtherapeutics.com
- Total disclosed funding: $40M
- Latest round: Series A (Feb 23, 2023)
- Investors on record: 6

## About

Based in New York, US, and founded in 2021 by Chairman Kevin Ryan, CEO Blake Mandell, and Chief Scientific Advisor Benjamin Kelmendi, Transcend Therapeutics, Inc. operates as a psychoactive medicine's provider for neuropsychiatric disease. In Q2 2026, Otsuka Pharmaceutical Co., Ltd., a portfolio company of? AN Ventures acquired Transcend Therapeutics, Inc. from Alumni Ventures Group, FJ Labs, Alpha Wave Global, Emerald Development Managers, Global Founders Capital, and Integrated.vc for USD 1.2 billion. 


Transcend Therapeutics develops psychoactive drugs for patients suffering from post-traumatic stress disorder (PTSD) and depression. The company provides a compound known as TSND-201, which is medicine for short-acting and mild psychological treatment for PTSD. The firm serves industries such as biotechnology, Pharmacy, healthcare, and hospital. 

The acquisition aims to support strengthens Otsuka Pharmaceutical Co., Ltd.’s build its psychiatric services and solutions by integrating Transcend Therapeutics, Inc. capabilities.

## Funding rounds

- Series A, Feb 23, 2023, $40M — Alpha Wave Global, Global Founders Capital, Emerald Development Managers, Integrated.vc
- Series A, Dec 17, 2021 — Alumni Ventures Group, FJ Labs

## Investors

- Alumni Ventures Group (https://capitalatlas.ai/funds/alumni-ventures-group) — Series A
- FJ Labs (https://capitalatlas.ai/funds/fj-labs) — Series A
- Alpha Wave Global (https://capitalatlas.ai/funds/alpha-wave-global) — Series A
- Global Founders Capital (https://capitalatlas.ai/funds/global-founders-capital) — Series A
- Emerald Development Managers (https://capitalatlas.ai/funds/emerald-development-managers) — Series A
- Integrated.vc — Series A